HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nestle Health Science Plans Continuum Of Care

This article was originally published in The Tan Sheet

Executive Summary

Nestle's announcement that its Health Science division is buying gastrointestinal drug developer and diagnostics firm Prometheus Laboratories takes the food company in a new direction, raising questions about Nestle's possible pharmaceutical play.

You may also be interested in...

In Brief

Nestle takes stake in constipation cure firm

Nestle Dovetails Health Sciences Offerings With Purchase Of Diagnostics Firm

Nestle Health Science adds gastrointestinal diagnostic services to its nutritional health business with its Prometheus Laboratories acquisition.

Nestle Claims "Pioneer" Mantle With Nutrition Business Expansion

Nestle will invest $500 million in the next 10 years to expand its medical nutrition business and help "pioneer a new industry between food and pharma" that the firm's executives estimate will be worth $100 billion to $150 billion





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts